Imagify Perfusion Stress Echo would be many potential advantages over nuclear stress tests have exposed including faster results, lower costs and no radioactivity. More than 10 million stress imaging procedures are performed in the U.S., in the U.S., heart disease, to identify the main cause of death in the United States. – These Phase 3 data to the growing number of efficacy and safety data on Imagify add now now in more than 1,000 patients, and further notes that Imagify that agent is an excellent perfusion imaging – superior to standard stress echocardiography, determine perfusion to be assessed, and only as accurate as nuclear stress test, said Roxy Senior, director of echocardiography in the Cardiology at Northwick Park Hospital and the Imperial College of Medicine, London, UK, and lead investigator in the RAMP -.
Accuracy, sensitivity and specificity: non-inferiority and superiority analysis, compared to nuclear weapons, was measured in three primary endpoints. Disease RAMP-1 and-2 and 377 285 consisted evaluable efficacy angina patients. Patients from 28 international sites underwent Imagify Perfusion Stress Echo imaging and nuclear at rest and during dipyridamole stress. The images were the presence of wall motion and / or perfusion by independent blinded reader interprets .Over the treatment of obesity with a liraglutideexcess weight is an increasing a global problem, Medicines Agency formulated with an increased risk to the develop type 2 diabetes and other serious illnesses. It is generally recognized that is the best way Obesity through exercise and healthy diet has. However, it is also recognized to for some people it is and and the necessary weight reduction even with considerable effort. With people who have a high risk for obesity-related complications as patient additional risk factors such as arthritis high blood pressure, the cardiovascular disease or diabetes, supportive care products with medicine risk of complications to reduce the risk of complications and improving the to be quality of life..
To be are listed at the New York Stock Exchange under the symbol ‘NVO’.
Novo Nordisk announced clinical results of a 32-week open-label extension of a 20-week Stage 2 obesity study where treatment with liraglutide, to once-daily human GLP-1 – analog overweight people in obese people not diabetic. Novo Nordisk reports initial results of from the first 20 weeks of phase 2 study in November 2007.. Novo Nordisk is a pharma company and global market leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis, Human growth hormone therapy and hormone replacement therapies. Novo Nordisk manufactures and markets pharmaceutical products and services that.